Form 4: Metagenomi Therapeutics: Insider Stock Transactions

Matthew Wein, General Counsel of Metagenomi Therapeutics, reported transactions involving restricted stock units and stock options.

Summary

• Matthew Wein, General Counsel, Compliance Officer and Corporate Secretary of Metagenomi Therapeutics, Inc., reported transactions on April 1, 2026.
• He acquired 11,000 shares of Common Stock, which represent restricted stock units (RSUs).
• These RSUs have a vesting schedule: 25% vest on June 5, 2027, and the remainder vests quarterly thereafter, contingent on continued service.
• Additionally, he acquired a stock option for 68,000 shares with an exercise price of $1.34.
• This stock option vests in stages: 25% on April 1, 2027, and the remaining 75% in 36 equal monthly installments thereafter, also subject to continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it details standard executive compensation and incentive grants rather than significant financial performance or strategic shifts.

Positives

• Acquisition of 11,000 restricted stock units (RSUs) by a key executive, indicating continued commitment to the company.
• Grant of stock options for 68,000 shares to a key executive, aligning executive incentives with long-term company performance.
• Vesting schedules for both RSUs and stock options are tied to continued service, promoting employee retention.

Risks

• Vesting of RSUs and stock options is contingent on the Reporting Person's continued service with the Issuer, implying a risk of forfeiture if service is terminated.
• The stock option exercise price of $1.34 suggests that the company's stock price needs to exceed this level for the options to be profitable.

Future Outlook

The vesting schedules for the RSUs and stock options indicate a long-term incentive structure, with significant portions vesting in 2027 and thereafter, contingent on continued employment.

Industry Context

StockSavvy.ai notes that the reporting of stock options and RSUs by key executives is a common practice in the biotechnology and pharmaceutical sectors, serving to align management's financial interests with those of shareholders and incentivize long-term growth and value creation.

Stakeholder Impact

• Shareholders: The grants align executive incentives with long-term company performance, potentially benefiting shareholders if the stock price increases.
• Employees: The vesting schedules encourage continued service from key personnel.
• Management: Matthew Wein receives equity-based compensation tied to his continued employment and the company's success.

Next Steps

• Continued service by Matthew Wein to meet vesting requirements for RSUs and stock options.
• Monitoring of Metagenomi Therapeutics' stock performance relative to the stock option exercise price.

Key Dates

Keywords

Metagenomi Therapeutics, MGX, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Matthew Wein, Executive Compensation, SEC Filing